 The poster presentation will show interim data for HPN424 from its ongoing dose escalation Phase 1 clinical trial in patients with metastatic castration-resistant prostate cancer mCRPC. HPN424 targets prostate-specific membrane antigen PSMA and is based on Harpoons proprietary Tri-specific T cell Activating Construct TriTAC platform designed to recruit a patients own immune cells to target and kill tumor cells. 